Reply to thread

Message

<blockquote data-quote="Andy Ful" data-source="post: 1018764" data-attributes="member: 32260">I admire the effort of the testers. Some tests (especially on MT) are interesting because they can show the weak points of the tested software and other aspects of the applied protection. <img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="smilie smilie--sprite smilie--sprite130" alt="(y)" title="Thumbs up&nbsp; &nbsp; (y)" loading="lazy" data-shortname="(y)" />But, one thing should be realized. The weak points do not translate to protection in the wild. We have similar examples in real life. Most people in the world could die from Ebola, but only a very small percentage do. This is a striking result compared to malaria with about 250 million cases per year (over 600 000 deaths).The problem is when the AV vendor ignores the problem for too long. It seems that most AV vendors can react similarly to this problem because the differences in AV protection are not big.</blockquote>

[QUOTE="Andy Ful, post: 1018764, member: 32260"] I admire the effort of the testers. Some tests (especially on MT) are interesting because they can show the weak points of the tested software and other aspects of the applied protection. (y) But, one thing should be realized. The weak points do not translate to protection in the wild. We have similar examples in real life. Most people in the world could die from Ebola, but only a very small percentage do. This is a striking result compared to malaria with about 250 million cases per year (over 600 000 deaths). The problem is when the AV vendor ignores the problem for too long. It seems that most AV vendors can react similarly to this problem because the differences in AV protection are not big. [/QUOTE]

Verification